COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

UC San Diego Health System Now Offers Latest Catheter Ablation Therapy Using Heat Energy for Patients with Abnormal Heart Rhythms

 

February 16, 2012  |  

FDA-approved non-surgical technology alters heart tissue that triggers atrial fibrillation

UC San Diego Sulpizio Cardiovascular Center is now offering patients with atrial fibrillation the breakthrough benefits of heat energy, or radio frequency waves, to irreversibly alter heart tissue that triggers an abnormal heart rhythm or arrhythmia. The THERMOCOOL® SF Catheter is an FDA-approved outpatient procedure for an early-stage form of the condition called paroxysmal atrial fibrillation, when recurring symptoms are unresponsive to medicine. Patients typically experience rapid heartbeats that can lead to debilitating fatigue, dizziness, fainting or shortness of breath if left untreated.

Gregory Feld 
Gregory Feld, MD
“Atrial fibrillation has a devastating impact on more than 2.7 million Americans, yet for many patients unresponsive to medication, traditional treatment options are limited,” said    Gregory Feld, MD, professor of medicine at University of California, San Diego and Director of the Cardiac Electrophysiology Program at UC San Diego Sulpizio Cardiovascular Center. “This catheter ablation technology is the latest treatment alternative for patients dealing with the disabling effects of cardiac arrhythmias, such as paroxysmal atrial fibrillation. This is a viable option for patients who do not benefit from their first medication.”

Atrial fibrillation causes the upper heart chambers to beat rapidly and uncontrollably, and is characterized by disorganized electrical activity in the heart. This results in an irregular pulse, and sometimes a “fluttering” feeling in the chest. An episode can last just seconds, or occur for minutes, hours or even days. Paroxysmal atrial fibrillation is an early-stage form of the condition, where episodes occur repeatedly but stop on their own, often in a few hours or less.

Performed by an electrophysiologist (EP), catheter ablation is a non-surgical procedure that addresses the underlying cause of arrhythmias. In real time, the clinician first pinpoints the source of irregular electrical activity using a 3-D mapping system, similar to a GPS device in your car. Guided by this map, the clinician directs a specialized catheter through the heart to the source of the abnormal electrical impulses. A small electrode in the tip of the catheter generates radio frequency waves that have enough heat to alter targeted areas of heart tissue. This process blocks the electrical impulses that can cause heart rhythm disorders.

Unlike traditional catheter technologies, the THERMOCOOL® SF catheter uniformly delivers a cooling saline solution through the catheter, allowing for cooling of the entire catheter tip. Thus, the tip temperature does not rise significantly during ablation, which reduces the risk for clotting, and enhances treatment safety.

This outpatient procedure takes approximately two-to-four hours, with some patients returning home the next day. The result is either a long-term reduction in the number of arrhythmias experienced and the severity of symptoms, or a permanent return to a more normal heart rhythm.

Atrial fibrillation is growing in prevelance. Up to 12 million Americans will have the condition by 2050. While not life-threatening, atrial fibrillation is a leading cause of stroke among people 65 years and older. 

# # #

Media Contact: Kim Edwards, 619-543-6163, kedwards@ucsd.edu


Related Specialties



Media Contact

Share This Article


Related News

3/3/2021
UC San Diego School of Medicine researchers develop an automated process to test city sewage for SARS-CoV-2, allowing them to forecast the region’s COVID-19 caseload one to two weeks ahead of clinical ...
3/2/2021
Researchers at UC San Diego School of Medicine and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.
3/2/2021
Researchers at UC San Diego Health see a possible way to detect heart disease through the eye.
3/1/2021
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality ...



Follow Us